Corazzelli, G <br/><br/>
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  May 2006 
 - iv18-24 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdj994  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Combined Modality Therapy<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Hematopoietic Stem Cell Mobilization<br/>Humans<br/>Ifosfamide--administration & dosage<br/>Lymphoma, B-Cell--pathology<br/>Lymphoma, Follicular--pathology<br/>Lymphoma, Large B-Cell, Diffuse--pathology<br/>Lymphoma, Mantle-Cell--pathology<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--pathology<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Pilot Projects<br/>Remission Induction<br/>Rituximab<br/>Salvage Therapy<br/>Stem Cell Transplantation<br/>Survival Rate<br/>Transplantation, Autologous<br/>Treatment Outcome<br/>Gemcitabine